secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001104659-23-089298
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel Q2 2023 net loss $5.4M; cash $10.2M, runway to end of 2023
-------------------------------------------------------------------

- Net loss of $5.4M for Q2 2023 vs $4.6M Q2 2022; cash $10.2M at June 30, 2023 (down from $18.3M Dec 2022).
- R&D expenses $4.7M in Q2 2023 vs $4.2M Q2 2022; fadraciclib $3.0M, plogosertib $1.4M.
- Cash expected to fund programs through end of 2023; discretionary cuts could extend to Q2 2024.
- Phase 1/2 data for fadraciclib and plogosertib expected in 2023; tumor shrinkage observed in several cancer types.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/0001104659-23-089298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/tm2323211d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer